Correction
The authors [1] note that the standard errors in Table 3 (Table 1 here) are actually standard deviations. The reference to standard errors in the footnote has now been edited accordingly.
Table 1.
Summary of laboratory parameters
| PBO + MET (n = 137) | DAPA 2.5 mg + MET (n = 137) | DAPA 5 mg + MET (n = 137) | DAPA 10 mg + MET (n = 135) | |
|---|---|---|---|---|
|
Sodium (mmol/L) |
|
|
|
|
| n |
72 |
77 |
87 |
93 |
| Baseline |
138.9 (2.3) |
138.5 (2.9) |
138.6 (2.3) |
139.1 (2.2) |
| Change at week 102 |
-0.04 (2.7) |
0.2 (2.8) |
0.1 (2.6) |
0.1 (2.6) |
|
P vs PBO + MET |
|
0.1434 |
0.1905 |
0.3978 |
|
Potassium (mmol/L) |
|
|
|
|
| n |
72 |
77 |
87 |
93 |
| Baseline |
4.35 (0.47) |
4.34 (0.46) |
4.37 (0.39) |
4.37 (0.43) |
| Change at week 102 |
-0.08 (0.55) |
-0.01 (0.45) |
-0.05 (0.35) |
-0.07 (0.47) |
|
P vs PBO + MET |
|
0.3366 |
0.4563 |
0.9918 |
|
Serum creatinine (μmol/L) |
|
|
|
|
| n |
72 |
77 |
88 |
93 |
| Baseline |
76.9 (17.9) |
78.7 (18.1) |
79.6 (19.3) |
77.8 (17.8) |
| Change at week 102 |
-0.9 (10.3) |
-1.8 (9.7) |
-3.5 (12.7) |
-2.7 (10.6) |
|
P vs PBO + MET |
|
0.9954 |
0.4720 |
0.9032 |
|
Serum uric acid (μmol/L)
a
|
|
|
|
|
| n |
28 |
35 |
47 |
57 |
| Baseline |
314 (79) |
322 (80) |
323 (88) |
323 (80) |
| Change at week 102 |
-1.78 (54.13) |
-55.9 (50.32) |
-46.4 (64.36) |
-52.9 (64.36) |
|
P vs PBO + MET |
|
0.0054 |
0.0013 |
0.0002 |
|
Blood urea nitrogen (mmol/L) |
|
|
|
|
| n |
72 |
77 |
88 |
93 |
| Baseline |
5.33 (1.55) |
5.51 (1.41) |
5.65 (1.81) |
5.34 (1.41) |
| Change at week 102 |
0.56 (1.24) |
0.70 (1.54) |
0.42 (1.87) |
0.73 (1.44) |
|
P vs PBO + MET |
|
0.2299 |
0.4169 |
0.0845 |
|
Haematocrit (%) |
|
|
|
|
| n |
71 |
78 |
87 |
93 |
| Baseline |
42.61 (3.90) |
42.38 (3.99) |
42.15 (3.59) |
42.88 (3.95) |
| Change at week 102 |
-1.43 (3.29) |
0.84 (2.53) |
1.35 (2.48) |
1.54 (2.78) |
|
P vs PBO + MET |
|
<0.0001 |
<0.0001 |
<0.0001 |
|
Haemoglobin (g/L) |
|
|
|
|
| n |
71 |
78 |
87 |
94 |
| Baseline |
142.8 (13.45) |
142.5 (14.25) |
141.6 (12.19) |
143.6 (13.10) |
| Change at week 102 |
-4.9 (10.14) |
1.5 (7.73) |
3.1 (8.40) |
4.1 (8.84) |
|
P vs PBO + MET |
|
<0.0001 |
<0.0001 |
<0.0001 |
|
Systolic blood pressure (mm Hg) |
|
|
|
|
| n |
72 |
78 |
88 |
94 |
| Baseline |
128 (15) |
127 (14) |
127 (14) |
126 (16) |
| Change at week 102 |
1.5 (13.7) |
0.7 (16.1) |
-1.1 (13.2) |
-0.3 (15.0) |
|
P vs PBO + MET |
|
0.1111 |
0.0136 |
0.0067 |
|
Diastolic blood pressure (mm Hg) |
|
|
|
|
| n |
72 |
78 |
88 |
94 |
| Baseline |
81 (9) |
80 (9) |
81 (9) |
79 (10) |
| Change at Week 102 |
-1.0 (7.9) |
-0.1 (8.1) |
-1.5 (8.1) |
-1.2 (10.1) |
| P vs PBO + MET | 0.6605 | 0.2140 | 0.1075 |
Data are means (SD) at baseline or mean changes (SD) from baseline at week 102 including data after rescue unless noted. n is the number of treated patients with non-missing baseline and Week 102 values for the specific test. aExcluding data after rescue. Abbreviations: SD standard deviation, SE standard error, PBO placebo, MET metformin, DAPA dapagliflozin.
This is a Correction article on http://www.biomedcentral.com/1741-7015/11/43.
Pre-publication history
The pre-publication history for this paper can be accessed here:
Contributor Information
Clifford J Bailey, Email: c.j.bailey@aston.ac.uk.
Jorge L Gross, Email: jorgeluizgross@gmail.com.
Delphine Hennicken, Email: delphine.hennicken@bms.com.
Nayyar Iqbal, Email: nayyar.iqbal@bms.com.
Traci A Mansfield, Email: traci.mansfield@bms.com.
James F List, Email: james.list@bms.com.
References
- Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Medicine. 2013;11:43. doi: 10.1186/1741-7015-11-43. [DOI] [PMC free article] [PubMed] [Google Scholar]